Effectiveness and safety of dual influenza and pneumococcal vaccination versus separate administration or no vaccination in older adults: a meta-analysis

Expert Review of Vaccines

Volumn 17, Issue 7, 2018, Pages 653-663

  Yin, Mingjuan ^a   Huang, Lingfeng ^a   Zhang, Yan ^a   Yu, Na ^a   Xu, Xiaojia ^a   Liang, Yaping ^a   Ni, Jindong ^a  

^a GUANGDONG MEDICAL UNIVERSITY   (China)

Author keywords

Effectiveness; elderly; influenza vaccination; pneumococcal vaccination; safety

Indexed keywords

INFLUENZA VACCINE; PLACEBO; PNEUMOCOCCUS VACCINE; VACCINE;

ADULT; ALL CAUSE MORTALITY; ARTHRALGIA; ARTICLE; CHILL; CLINICAL EFFECTIVENESS; DRUG SAFETY; FATIGUE; FEVER; HEADACHE; HOSPITALIZATION; HUMAN; INFECTION PREVENTION; INFLUENZA; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; META ANALYSIS; MYALGIA; OUTCOME ASSESSMENT; PNEUMOCOCCAL INFECTION; PNEUMONIA; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIA; VACCINATION; AGED; COMPARATIVE STUDY; IMMUNOLOGY; PROCEDURES; STATISTICS AND NUMERICAL DATA;

AGED; HOSPITALIZATION; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; VACCINATION; VACCINES, COMBINED;

EID: 85050004085     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1080/14760584.2018.1495077     Document Type: Article

References (49)

1. Wroe PC, Finkelstein JA, Ray GT, et al. Aging population and future burden of pneumococcal pneumonia in the United States. J Infect Dis. 2012;205(10):1589–1592
2. World Health Organization. 23-valent pneumococcal polysaccharide vaccine. WHO position paper. Wkly Epidemiol Rec. 2008;83(42):373–384
3. Goronzy JJ, Weyand CM., Understanding immunosenescence to improve responses to vaccines. Nat Immunol. 2013;14(5):428–436
4. van Essen GA, Palache AM, Forleo E, et al. Influenza vaccination in 2000: recommendations and vaccine use in 50 developed and rapidly developing countries. Vaccine. 2003;21(16):1780–1785
5. Trombetta CM, Gianchecchi E, Montomoli E., Influenza vaccines: evaluation of the safety profile. Hum Vaccin Immunother. 2018;14(3):657–670
6. Jefferson T, Rivetti D, Rivetti A, et al. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet. 2005;366(9492):1165–1174
7. Centers for Disease Control and Prevention (CDC), Advisory Committee on Immunization Practices. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep. 2010;59(34):1102–1106
8. Seo YB, Choi WS. Comparison of immunogenicity and safety of an influenza vaccine administered concomitantly with a 13-valent pneumococcal conjugate vaccine or 23-valent polysaccharide pneumococcal vaccine in the elderly. Clin Exp Vaccine Res. 2017;6(1):38–44
9. Falkenhorst G, Remschmidt C, Harder T, et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPV23) against pneumococcal disease in the elderly: systematic review and meta-analysis. PLoS One. 2017;12(1):e0169368
10. Solanki BB, Juergens C, Chopada MB, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in adults 50 to 65 years of age in India: an open-label trial. Hum Vaccin Immunother. 2017;13(9):2065–2071
11. Ciprero K, Zykov KA, Briko NI, et al. Safety and immunogenicity of a single dose 23-valent pneumococcal polysaccharide vaccine in Russian subjects. Hum Vaccin Immunother. 2016;12(8):2142–2147
12. Kong Y, Zhang W, Jiang Z, et al. Immunogenicity and safety of a 23-valent pneumococcal polysaccharide vaccine in Chinese healthy population aged >2 years: a randomized, double-blinded, active control, phase III trial. Hum Vaccin Immunother. 2015;11(10):2425–2433
13. Walter ND, Taylor TH, Shay DK, et al. Influenza circulation and the burden of invasive pneumococcal pneumonia during a non-pandemic period in the United States. Clin Infect Dis. 2010;50(2):175–183
14. Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis. 2008;198(7):962–970
15. Nichol KL. The additive benefits of influenza and pneumococcal vaccinations during influenza seasons among elderly persons with chronic lung disease. Vaccine. 1999;17 Suppl 1:S91–3
16. Gilchrist SA, Nanni A, Levine O. Benefits and effectiveness of administering pneumococcal polysaccharide vaccine with seasonal influenza vaccine: an approach for policymakers. Am J Public Health. 2012;102(4):596–605
17. Honkanen PO, Keistinen T, Kivela SL. Reactions following administration of influenza vaccine alone or with pneumococcal vaccine to the elderly. Arch Intern Med. 1996;156(2):205–208
18. Frenck RW, Jr., Gurtman A, Rubino J, et al. Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults. Clin Vaccine Immunol. 2012;19(8):1296–1303
19. Honkanen PO, Keistinen T, Miettinen L, et al. Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older. Vaccine. 1999;17:2493–2500
20. Koivula I, Sten M, Leinonen M, et al. Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial. Am J Med. 1997;103(4):281–290
21. Zhang YY, Tang XF, Du CH, et al. Comparison of dual influenza and pneumococcal polysaccharide vaccination with influenza vaccination alone for preventing pneumonia and reducing mortality among the elderly: a meta-analysis. Hum Vaccin Immunother. 2016;12(12):3056–3064
22. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–12
23. Wells GA, Shea BJ, O'Connell D, et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analysis. Appl Eng Agric. 2012;18(6):727–734
24. Orenstein WA, Bernier RH, Hinman AR. Assessing vaccine efficacy in the field. Further observations. Epidemiol Rev. 1988;10:212–241
25. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. Bmj. 2003;327(7414):557–560
26. Christenson B, Hedlund J, Lundbergh P, et al. Additive preventive effect of influenza and pneumococcal vaccines in elderly persons. Eur Respir J. 2004;23(3):363–368
27. Furumoto A, Suetsugu T, Aizawa H, et al. Additive effects of pneumococcal polysaccharide vaccine in combination with influenza vaccine on acute exacerbations in patients with chronic lung diseases. Respirology (Carlton, Vic). 2006;11:A128 [o-1-6]
28. Skull SA, Andrews RM, Byrnes GB, et al. Prevention of community-acquired pneumonia among a cohort of hospitalized elderly: benefit due to influenza and pneumococcal vaccination not demonstrated. Vaccine. 2007;25(23):4631–4640
29. Hung IF, Leung AY, Chu DW, et al. Prevention of acute myocardial infarction and stroke among elderly persons by dual pneumococcal and influenza vaccination: a prospective cohort study. Clin Infect Dis. 2010;51(9):1007–1016
30. Kawakami K, Ohkusa Y, Kuroki R, et al. Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan. Vaccine. 2010;28(43):7063–7069
31. Chan TC, Hung IFN, Luk JKH, et al. Prevention of mortality and pneumonia among nursing home older adults by dual pneumococcal and seasonal influenza vaccination during a pandemic caused by novel pandemic influenza A (H1N1). J Am Med Dir Assoc. 2012;13(8):698–703
32. Chang YC, Chou YJ, Liu JY, et al. Additive benefits of pneumococcal and influenza vaccines among elderly persons aged 75 years or older in Taiwan–a representative population-based comparative study. J Infect. 2012;65(3):231–238
33. Mahamat A, Daurès JP, De Wazières B. Additive preventive effect of influenza and pneumococcal vaccines in the elderly results of a large cohort study. Hum Vaccin Immunother. 2013;9(1):128–135
34. Li C, Gubbins PO, Chen GJ. Prior pneumococcal and influenza vaccinations and in-hospital outcomes for community-acquired pneumonia in elderly veterans. J Hosp Med. 2015;10(5):287–293
35. Song JY, Lee JS, Wie SH, et al. Prospective cohort study on the effectiveness of influenza and pneumococcal vaccines in preventing pneumonia development and hospitalization. Clin Vaccine Immunol. 2015;22(2):229–234
36. Schwarz TF, Flamaing J, Rumke HC, et al. A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged >/=65 years. Vaccine. 2011;29(32):5195–5202
37. Song JY, Cheong HJ, Tsai TF, et al. Immunogenicity and safety of concomitant MF59-adjuvanted influenza vaccine and 23-valent pneumococcal polysaccharide vaccine administration in older adults. Vaccine. 2015;33(36):4647–4652
38. Ofori-Anyinam O, Leroux-Roels G, Drame M, et al. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine co-administered with a 23-valent pneumococcal polysaccharide vaccine versus separate administration, in adults >/=50years of age: results from a phase III, randomized, non-inferiority trial. Vaccine. 2017;35(46):6321–6328
39. Song JY, Cheong HJ, Hyun HJ, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine and an MF59-adjuvanted influenza vaccine after concomitant vaccination in 60-year-old adults. Clin Exp Vaccine Res. 2017;35(2):313–320
40. Huss A, Scott P, Stuck AE, et al. Efficacy of pneumococcal vaccination in adults: a meta-analysis. Cmaj. 2009;180(1):48–58
41. Christenson B, Lundbergh P. Comparison between cohorts vaccinated and unvaccinated against influenza and pneumococcal infection. Epidemiol Infect. 2002;129(3):515–524
42. Christenson B, Pauksen K, Sylvan SP. Effect of influenza and pneumococcal vaccines in elderly persons in years of low influenza activity. Virol J. 2008;5:52
43. Nichol KL, Wuorenma J, von Sternberg T. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch Intern Med. 1998;158(16):1769–1776
44. Guevara RE, Butler JC, Marston BJ, et al. Accuracy of ICD-9-CM codes in detecting community-acquired pneumococcal pneumonia for incidence and vaccine efficacy studies. Am J Epidemiol. 1999;149(3):282–289
45. van de Garde EM, Oosterheert JJ, Bonten M, et al. International classification of diseases codes showed modest sensitivity for detecting community-acquired pneumonia. J Clin Epidemiol. 2007;60(8):834–838
46. You JH, Wong WC, Ip M, et al. Cost-effectiveness analysis of influenza and pneumococcal vaccination for Hong Kong elderly in long-term care facilities. J Epidemiol Community Health. 2009;63(11):906–911
47. Smith KJ, Lee BY, Nowalk MP, et al. Cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds. Vaccine. 2010;28(48):7620–7625
48. Fedson DS, Nicolas-Spony L, Klemets P, et al. Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe. Expert Rev Vaccines. 2011;10(8):1143–1167
49. Giese C, Mereckiene J, Danis K, et al. Low vaccination coverage for seasonal influenza and pneumococcal disease among adults at-risk and health care workers in Ireland, 2013: the key role of GPs in recommending vaccination. Vaccine. 2016;34(32):3657–3662